Inovio Pharmaceuticals Inc (INO) FinancialsINOInovio Pharmaceuticals Inc

Evaluating the bottom line, Inovio Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -409.87%, provide a clear picture of how effectively INO converts its operational activities into shareholder value.

In the context of the broader market, INO competes directly with industry leaders such as TLSA and BGM. With a market capitalization of $133.38M, it holds a significant position in the sector. When comparing efficiency, INO's gross margin of N/A stands against TLSA's N/A and BGM's 17.55%. Such benchmarking helps identify whether Inovio Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has a forward P/E of 16.58, indicating potential for future earnings growth, although it reported a net income loss of -6012458.00 USD in Q2 2026.